Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 17, 2025 01:00 ET | Source: VERAXA Biotech

VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC

ZURICH, SWITZERLAND, July 17, 2025 -- VERAXA Biotech AG (“VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp., a Cayman Islands exempted...
May 05, 2025 01:00 ET | Source: VERAXA Biotech GmbH

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

ZURICH, SWITZERLAND, May 5, 2025 -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp....
April 23, 2025 01:09 ET | Source: VERAXA Biotech GmbH

VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

VERAXA’s Novel BiTAC Platform has the Potential to Deliver Multiple Next-Generation Solid Tumor Cancer Therapies, Including Novel Antibody-Drug Conjugate ("ADC") and Bispecific T-cell Engager ("TCE")...
August 10, 2023 07:00 ET | Source: Immatics N.V.

Immatics beginnt klinische Phase-1/2-Studie zur Untersuchung des bispezifischen TCR-Kandidaten IMA402 gegen die Zielstruktur PRAME bei Patienten mit fortgeschrittenen soliden Tumoren

TCER® IMA402 ist der erste gegen die Zielstruktur PRAME gerichtete bispezifische TCR-Kandidat der nächsten Generation mit verlängerter Halbwertszeit in der klinischen EntwicklungPatientenrekrutierung...
August 10, 2023 07:00 ET | Source: https://immatics.com/

Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors

TCER® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the clinicPatient enrollment for IMA402 Phase 1/2 trial underwayThe trial will evaluate safety,...
December 14, 2021 06:59 ET | Source: Immatics N.V.

Immatics und Bristol Myers Squibb schließen weltweite Exklusivlizenz für Immatics‘ bispezifisches TCR-Programm IMA401 ab

Bristol Myers Squibb sichert sich weltweite Exklusivlizenz für Immatics‘ bispezifisches TCR-Programm IMA401; die Unternehmen werden bei der Entwicklung zusammenarbeiten, Immatics behält Option auf die...
December 14, 2021 06:59 ET | Source: https://immatics.com/

Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401

Bristol Myers Squibb secures global exclusive license to Immatics’ TCR bispecific program IMA401; companies will collaborate on development with Immatics retaining a co-promotion option in the...
July 09, 2020 07:00 ET | Source: https://immatics.com/

Immatics Announces Board of Directors Additions Following Public Listing on NASDAQ

Houston, Texas and Tuebingen, Germany, July 09, 2020 (GLOBE NEWSWIRE) -- Houston, Texas and Tuebingen, Germany, July 9, 2020 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage...
July 02, 2020 07:00 ET | Source: Immatics N.V.

Immatics schließt Fusion mit Arya ab und gibt US-Börsennotierung an der NASDAQ bekannt

Houston, Texas und Tübingen, Deutschland, July 02, 2020 (GLOBE NEWSWIRE) -- Die Fusion mit Arya Sciences Acquisition Corporation, eine von Perceptive Advisors gegründete „SPAC“, wurde am 1....
July 02, 2020 07:00 ET | Source: https://immatics.com/

Immatics Announces Completion of Business Combination and Listing on NASDAQ

Houston, Texas and Tuebingen, Germany, July 02, 2020 (GLOBE NEWSWIRE) -- The business combination transaction with Arya Sciences Acquisition Corporation, a special purpose acquisition company...